

1ST BALTIC CONFERENCE ON GYNAECOLOGICAL ONCOLOGY

November 9, 2018,
Vilnius, Lithuania

CONFERENCE PROGRAMME

8:00-8:30 Registration		
Session 1		
Chairs: B. Brasiuniene, Lithuania & K. Ojamaa, Estonia		
8:30-8:35	Welcome	Prof. F. Jankevicius, Director of National Cancer Institute of Lithuania
8:35-8:50	New developments in the treatment of gynaecological cancer	Prof. U. Matulonis, Director and Program Leader, Dana-Farber Cancer Institute, USA
8:50-9:10	Epidemiology of gynaecological cancers	G. Smailyte, National Cancer Institute, Lithuania
9:10-9:40	Presentation of EORTC Gynecological Cancer Group	N. Ottevanger, Chair of EORTC gynecological cancer group, Radboud University Nijmegen Medical Centre, Netherlands
9:40-10:10	„Nordic collaboration: presentation of NSGO and NSGO- CTU (clinical trial unit)“	A. Auranen, President of NSGO, Tampere University Hospital, Finland
10:10-10:30	Genetics of gynaecological cancer	Prof. S. Jarmalaite/R. Sabaliauskaite, National Cancer Institute, Lithuania
10:30-10:45	Liquid biopsy: clinical applications in gynaecological cancer	V. Brasiunas, Robert Ballanger Hospital, France
10:45-11:15 Coffee break		
OVARIAN CANCER		
Session 2		
Chairs: R. Vansevičiute-Petkeviciene & V. Rudaitis, Lithuania		
11:15-11:35	¹⁸ F-FDG PET/CT in gynaecological cancer	D. Jocius, Vilnius University Hospital Santaros Klinikos, Lithuania
11:35-11:50	Ovarian cancer imaging. Estonian experience	S. Remmer, North Estonia Medical Centre Foundation, Estonia
11:50-12:10	Ovarian cancer surgery. Estonian experience	K. Kukk, North Estonia Medical Centre Foundation, Estonia
12:10-12:30	Intraperitoneal chemotherapy and HIPEC in ovarian cancer patients. Experience of NCI	R. Ciurliene, National Cancer Institute, Lithuania
12:30-13:30 Lunch		
Chairs: A. Cesas, Lithuania & T. Jõgi, Estonia		
13:30-14:00	New therapeutic options for platinum resistant ovarian cancer	Prof. U. Matulonis, Director and Program Leader, Dana-Farber Cancer Institute, USA
14:00-14:15	Bevacizumab for treatment of ovarian cancer. Case reports	E. B. Juodzbaliene, Lithuanian University of Health Sciences Kauno Klinikos, Lithuania
14:15-14:35	<i>Satellite symposia</i>	Olaparib for treatment of ovarian cancer.
14:35-14:50		Case reports
14:50-15:20	<i>Web conference:</i> Treatment options in platinum resistant ovarian cancer: latest evidence and clinical experience	Prof. Bradley J. Monk, University of Arizona and Creighton University, Medical Director of US Oncology Research Gynecology Program, USA
15:20-15:50 Coffee break		
CERVICAL CANCER		
Session 3		
Chairs: Prof. A. Inciura, Lithuania & K. Kukk, Estonia		
15:50-16:10	<i>Web conference:</i> Update on systemic therapy for metastatic/ relapsed cervical cancer. Are there any new options beyond first line	Prof. Bradley J. Monk, University of Arizona and Creighton University, Medical Director of US Oncology Research Gynecology Program, USA
16:10-16:25	Cervical cancer	Estonian experience
16:25-16:40	surgery	Lithuanian experience
16:40-17:00	Brachytherapy for cervical cancer	I. Vaasna, Tartu University Clinics, Estonia
17:00-17:20	Systemic therapy of cervical cancer	V. Rudaitis, Vilnius University Hospital Santaros Klinikos, Lithuania
17:20-17:35	Bevacizumab for treatment of cervical cancer. Lithuanian experience	Prof. A. Inciura, Lithuanian University of Health Sciences Kauno Klinikos, Lithuania
17:35-17:55		K. Niinepuu, Tartu University Clinics, Estonia
17:20-17:35		B. Brasiuniene, National Cancer Institute, Lithuania
17:35-17:55 Coffee break		
OTHER GYNAECOLOGICAL CANCERS ISSUES		
Session 4		
Chairs: Prof. D. Vaitkiene, Lithuania & R. Saaron, Estonia		
17:55 -18:10	Uterine cancer surgery. Estonian experience	R. Saaron, East Tallinn Central Hospital, Estonia
18:10-18:30	Interstitial brachytherapy in gynaecological cancers. Experience of NCI	V. Nevulis-Obuchovska, National Cancer Institute, Lithuania
18:30-18:45	Pregnancy and cancer. Case reports	Prof. D. Vaitkiene, Lithuanian University of Health Sciences Kauno Klinikos, Lithuania
18:45-19:00		
19:00-19:10	Fertility preservation issues	Z. Gudleviciene, National Cancer Institute, Lithuania
19:10-19:20	Closing remarks – approaching	B. Brasiuniene, National Cancer Institute, Lithuania